The proto-oncogene BMI1 and its product, Bmi1, is overexpressed in various types of tumors, particularly in aggressive tumors and tumors resistant to conventional chemotherapy. BMI1/Bmi1 is also crucially involved in cancer-initiating cell maintenance, and is recurrently upregulated in mantle cell lymphoma (MCL), especially aggressive variants. Recently, side population (SP) cells were shown to exhibit tumor-initiating characteristics in various types of tumors. In this study, we show that recurrent MCL cases significantly exhibit upregulation of BMI1/Bmi1. We further demonstrate that clonogenic MCL SP shows such tumor-initiating characteristics as high tumorigenicity and self-renewal capability, and that BMI1 was upregulated in the SP from recurrent MCL cases and MCL cell lines. On screening for upstream regulators of BMI1, we found that expression of microRNA-16 (miR-16) was downregulated in MCL SP cells by regulating Bmi1 in the SPs, leading to reductions in tumor size following lymphoma xenografts. Moreover, to investigate downstream targets of BMI1 in MCL, we performed cross-linking/chromatin immunoprecipitation assay against MCL cell lines and demonstrated that Bmi1 directly regulated pro-apoptotic genes such as BCL2L11/Bim and PMAIP1/Noxa, leading to enhance anti-apoptotic potential of MCL. Finally, we found that a proteasome inhibitor bortezomib, which has been recently used for relapsed MCL, effectively induced apoptosis among MCL cells while reducing expression of Bmi1 and increasing miR-16 in MCL SP. These results suggest that upregulation of BMI1 and downregulation of miR-16 in MCL SP has a key role in the disease's progression by reducing MCL cell apoptosis. Our results provide important new insight into the pathogenesis of MCL and strongly suggest that targeting BMI1/Bmi1 might be an effective approach to treating MCL, particularly refractory and recurrent cases.
INTRODUCTION

Mantle cell lymphoma (MCL) is categorized as an indolent CD5
þ B-cell lymphoma and is difficult to effectively treat using conventional chemotherapy. 1, 2 Almost all MCL cases show translocation of t(11;14)(q13;q32), leading to cyclin D1 dysregulation. In addition to this translocation, MCL is associated with numerous genomic copy number alterations, including losses at 1p22, 2q14, 9p21, 11q22 and 17p, and gain/amplifications on chromosome 3 and at 8q24, 10p12 and 18q21. [1] [2] [3] [4] [5] [6] Among these, the target gene of the 10p12 amplification is a proto-oncogene, BMI1.
7 Its overexpression is recurrently observed in the blastoid variant of MCL, 3 which suggests BMI1 may have an important role in MCL tumorigenesis, especially in aggressive cases. Consistent with that idea, BMI1 is overexpressed in various types of tumors, particularly in aggressive tumors and tumors resistant to conventional chemotherapy. [8] [9] [10] [11] BMI1 encodes a member of the polycomb group family of proteins, and its product, Bmi1, is known to regulate several tumor-suppressor genes, including CDKN2A, PTEN, BCL2L11 and WWOX. [12] [13] [14] [15] [16] However, the role of BMI1/Bmi1 in the pathogenesis of MCL and its exact target genes has been insufficiently studied. It has also been proposed that Bmi1 maintains cancer-initiating cell populations in both leukemia and solid tumors. [17] [18] [19] [20] [21] Side population (SP) cells are identified based on their ability to export Hoechst 33342 dye via an ATP-binding cassette (ABC) membrane transporter, which gives SP cells a distinct low-staining pattern with Hoechst 33342. [22] [23] [24] [25] SP cells express high levels of various members of the ABC transporter family, including multidrug resistance protein 1 and breast cancer resistance protein, which are responsible for their drug resistance. [22] [23] [24] [25] SP cells have the ability of differentiation, repopulation, clonogenicity and self-renewal potential in various cancers, which are important characteristics of cancer-initiating cells. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Cancer-initiating cells are often identified from SPs. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Given that many different types of cancer-initiating cells overexpress ABC transporters, it seems reasonable to screen for stem-like fractions among cancer cells, based on this characteristic. Indeed, the SP has been isolated fromthus likely that SP cells from malignant lymphomas also show cancer-initiating cell characteristics, although this has not been studied previously.
These backgrounds lead us to hypothesize that (i) a protooncogene BMI1 might be crucially associated with disease progression of MCL, (ii) BMI1 might have crucial roles in the MCL-initiating cells. To investigate the role of BMI1, which also include detection for up regulator of BMI1 and downstream targets of BMI1, in MCL progression, we first examined BMI1 expression in normal CD5
þ B cells and in primary MCL cases at initial diagnosis and at recurrence, and found that relapsed MCL showed upregulation of BMI1/Bmi1. On the basis of this finding, we tried to examine expression of BMI1 in the SP of MCL, which might contain lymphoma-initiating cells.
RESULTS
Upregulation of BMI1 in recurrent MCL
We first examined BMI1 expression in primary specimens collected from 19 MCL patients at their initial diagnosis and from 10 patients in whom MCL recurred after a period of complete remission (CR). In all, 5 of the 10 relapsed samples were obtained from patients who also contributed to the 19 samples obtained at first diagnosis. We found that BMI1 expression was significantly higher at the time of recurrence (shown as 'R') than at initial diagnosis (shown as 'ID') or in normal CD5
þ B cells, which suggests BMI1 may have an important role in tumorigenesis, especially disease recurrence ( Figure 1a ).
We performed western blot analysis against a normal CD5 When we compared the expression at initial diagnosis and at recurrence, we confirmed the upregulation of Bmi1 at recurrence only. Three out of the five cases showed histological transformation at recurrence. One case showed leukemic transformation at recurrence (MCLP2). As an example, histopathological photographs taken at initial diagnosis and on recurrence in MCLP1 are shown in Figure 1b (lower panels). Morphologically, MCLP1 showed a histological transformation from 'classical/common type' at initial diagnosis to 'pleomorphic-like type' at recurrence. We performed immunohistochemical study of Bmi1 against MCLP1 case at first diagnosis and at recurrence and confirmed stronger expression of Bmi1 in the case recurrence than at first diagnosis ( Figure 1b) .
Clonogenic MCL SP cells show high tumorigenicity and self-renewal capability BMI1/Bmi1 is known to have a key role in cancer-initiating cells, [17] [18] [19] [20] [21] whereas the SP from both primary cancers and cancer cell lines is known to contain cancer-initiating cells. 14, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] We therefore evaluated the MCL SP for cancer-initiating characteristics. We initially screened for SP cells in seven MCL cell lines (Z138c, REC1, Jeko1, SP53, JVM2, NCEB1 and G519) and four B-cell lymphoma cell lines (FL18, OCI-Ly3, SUDHL4 and Raji), based on their ability to export Hoechst 33342 dye. Two MCL samples (MCLP1 and MCLP2) from patients with recurrent disease were also examined. Flow cytometry revealed SP cells in the tail region of the dot plots. We detected the SP and non-SP (main population, MP) fractions (%) from seven MCL cell lines and four B-cell lymphoma cell lines, with and without verapamil or reserpine treatment (Figures 2a and b) . The SP fractions in all examined cell lines ranged from 0.45% (Jeko1) to 11.4% (FL18; Figure 2b ). The SP and non-SP (MP) cells from the two primary specimens, which were stained with both CD19-PE and Hoechst 33342 were also detected (Figure 2c ). Low-level accumulation of intracellular Hoechst, characteristic of SP cells, was seen (left panel), and the population disappeared on inhibition of the ABC transporter using verapamil (100 mM; middle panel) or reserpine (50 mM; right panel).
To assess the clonogenicity of the SP, we performed colonyforming cell (CFC) assays with SP and MP cells sorted from the MCL cell lines (REC1, Z138c and Jeko1) and the primary sample (MCLP1). After 10 days, the sorted SP cells produced 12-14 (REC1), 12-32 (Z138c), 12-21 (Jeko1) and 7.5-13 (MCLP1) times more colonies than the corresponding MP cells. The shape and size of the colonies also differed significantly between the SP and MP cells (Figure 2d ).
Then to determine whether SP cells possess tumorigenic potential, we transplanted either SP or MP cells derived from REC1, Jeko1, and Z138c cells (1 Â 10 5 cells, n ¼ 5 each) into NOG mice, after which the resultant tumors grew much larger in mice transplanted with SP cells than MP cells (Figure 2e ). We termed these lesions 'first generation' tumors.
Self-renewal capability was examined by serial transplantation assays. To test for self-renewal of SP and MP cells from the aforementioned MCL cell lines, first-generation tumors were removed from the NOG mice, and the cells were subcultured and restained with Hoechst 33342 (Figure 2f , detailed information is described in the legend). A serial transplantation experiment was then conducted. We found that when transplanted the firstgeneration SPs were able to induce tumors (termed second generation), but the MPs did not induce first generation (Z138c, data not shown) or second-generation tumors (REC1 and Jeko1, Figure 2f ). Moreover, second-generation SPs were able to induce tumors (termed third generation). We also found that the SP gave rise to both SP and MP cells, whereas the MP produced only more MP cells. Collectively, these results suggest the clonogenic MCL SP contains key features of tumor-initiating cells, including capacities for self-renewal along with high tumorigenic potential.
Upregulation of BMI1/Bmi1 in MCL SP and the knockdown effects on the tumorigenicity As upregulation of BMI1 expression in cancer-initiating populations, [17] [18] [19] [20] [21] such as the SP, 21 is strongly associated with tumor development, we therefore screened for BMI1 expression in SP cells in five MCL cell lines and two relapsed primary specimens. We found that MCL SPs from both cell lines and primary samples showed greater expression of BMI1 than MPs. By contrast, FL18 cells derived from follicular lymphoma only weakly expressed BMI1, and there was no significant difference between expression in SP and MP cells (Figure 3a) . We further conducted western blot analysis of Bmi1, we found that Bmi1 was more strongly expressed in MCL SPs than MP cells (Figure 3b ) but not FL18. Our results suggest that upregulation of Bmi1 in MCL SP may contribute to enhance the tumorigenicity in MCL cell lines and recurrent cases.
To determine whether Bmi1 was required for tumorigenesis, we infected REC1 and Z138c cells with a robust inducible singlelentiviral vector encoding a knockdown reagent. Control short hairpin small interfering RNA (siRNA) or BMI1 siRNA was cloned into the inducible pLenti6/EmGFP-siRNA vector, which we then used to generate stable transfectants. Transduction of green fluorescent protein (GFP)-siBMI1, but not the control nontargeting siRNA (GFP-control), led to a significant reduction in the levels of BMI1 mRNA (Figure 3c , left panel). To assess the effect of siBMI1 on the SP cells' clonogenicity, we performed CFC assays using sorted Z138c SP and REC1 SP cells transfected either with GFP-control or with GFP-siBMI1. We found that the siBMI1 transfectants produced significantly fewer colonies than the controls (GFP-siBMI1: GFP-control, 1:3.5 to 1:5.9 in Z138c; 1:3.4 to 1:7.0 in REC1) (Figure 3c, right) . Furthermore, following subcutaneous inoculation of NOD/Shi-scid IL-2gnul (NOG) mice with Z138c SP or REC1 SP cells (1 Â 10 5 each) expressing GFPcontrol or GFP-siBMI1, tumors in mice receiving GFP-siBMIl expressing SP cells were significantly smaller than in those receiving SP cells transduced with GFP-control (Figure 3d) . Collectively, these results suggest that upregulated BMI1 in MCL SP contributes to the progression of MCL. Figure S1a) . Figure S1c; Figure 4a ). We found that miR-16 expression was weaker in SPs sorted from both cell lines and primary samples than in MPs (Figure 4a ). However, remaining miRNAs did not show such the difference between SPs and MPs. Altogether these results suggest that downregulation of miR-16 in MCL SP might contribute to the tumorigenicity.
To examine whether miR-16 might control Bmi1 in Z138c and REC1 cell lines, we conducted transduction of miR-16 or antisense oligo assay (ASO) for these cell lines (Figure 4b þ B cells or MCLP1 at 'ID' or MCLP2 at 'ID' , which is respectively assigned a value of 1.00. Lower panels: histopathological photograph (hematoxylin eosin (HE) staining) of MCLP1 at 'ID' and 'R' . Morphologically lymphoma cells at 'ID' showed small to medium sized nuclei, with slightly to markedly irregular nuclear contours, most closely resembling centrocytes, however cells at 'R' showed pleomorphic nuclei with large with oval to irregular nuclear counters, pale cytoplasm and often prominent nucleoli. Photograph of Bmi1 expressing cells (brown stained) of MCLP1 at ID and R are also shown under the HE panels.
SP, we examined Bmi1 expression against SP/MP of Z138c and REC1 with or without miR-16 transduction. Western blot analysis then revealed that Bmi1 expression was reduced in the SP of miR-16 transfectants (Figure 4d ). These results further support idea that miR-16 could negatively regulate Bmi1 in MCL SP.
To investigate the ability of miR-16 to reduce tumorigenicity in more detail, we measured tumor size subcutaneously inoculating To examine whether miR-16 can also reduce the clonogenicity of the MCL SP, we performed CFC assays using the SPs from Z138c and REC1 cells transfected either with miR-16 or with control. As shown in Figure 4f , colony counts were significantly lower with miR-16 transfectants than control cells. These data suggest that miR-16 reduces the clonogenicity of the MCL SP at least in part via downregulation of Bmi1.
Previously, it has been demonstrated that miR-15/16 could directly regulate Bmi1 in ovarian cancer. 35 To confirm whether miR-16 could potentially regulate Bmi1, we carried out luciferase reporter assays in Rat-1 fibroblasts stably expressing miR-16.
On insertion of the wild-type 3 0 un-translated region (UTR) of BMI1 into the reporter, we observed significant less luciferase activity in cells highly expressing miR-16 than in control cells transfected with empty vector (control). On the other hand, mutant bearing deletions at predicted miR-16 interaction sites rescued the luciferase activity. Thus miR-16 could target BMI1/Bmi1 by interfering 3 0 UTR of BMI1 mRNA ( Figure 4g ). These results showed that miR-16 could regulate BMI1/Bmi1 in MCL SP and the downregulation in SP may contribute aggressive tumorigenesis in MCL disease progression.
Knocking down BMI1 increases susceptibility to apoptosis via direct regulation of pro-apoptotic genes, PMAIP1 and BCL2L11 BMI1/Bmi1 was upregulated in recurrent cases of MCL, Z138c and REC1 cell lines, and MCL SP ( Figure 1; Figure 3a ). Given that both Z138c and REC1 cells show homozygous deletion of CDKN2A, 4 which is a well-known target of Bmi1, Bmi1 must also regulate other targets associating with anti-apoptotic activity in these cells. Recent studies demonstrated that Bmi1 Dysregulation of BMI1 and miR-16 in mantle cell lymphoma K Teshima et al could regulate pro-apoptotic genes such as BCL2L11/Bim and PMAIP1/Noxa in human multiple myeloma and mouse memory CD4 T cell, respectively. 15, 39 Thus, it was tempting to consider BMI1 might contribute tumorigenesis via regulating these apoptotic-related genes.
To examine whether Bmi1 might have a functional role of apoptosis regulation, we infected Z138c and REC1 cells with a robust inducible single-lentiviral vector knockdown reagent, pLKO-Tet-On, encoding either a non-targeting control siRNA or a well-established Bmi1-targeting siRNA (siBMI1). 15 Then using puromycin selection, stable polyclonal lines were generated. These MCL cell lines exhibited cytotoxicity when exposed to tetracycline at 450 mg/ml for 24 h (the IC 50 for tetracycline was 50 mg/ml in Z138c and REC1 cells). However, 10 mg/ml tetracycline was sufficient to induce siBMI1 in these cell lines. Tetracyclinemediated induction of siBMI1 (10 mg/ml for 72 h), but not induction of the control nontargeting siRNA, led to a remarkable reduction in Bmi1 (Figure 5a ) with a corresponding upregulation of two pro-apoptotic effector proteins, Noxa (Z138c and REC1) and Bim (REC1). In addition, we examined expression of Pten in Z138c and REC1, because Bmi1 could negatively regulate Pten. 14 However, we could not detect any correlation of expression between Bmi1 and Pten (Supplementary Figure S2) .
After staining the cellular DNA with propidium iodide or annexin V, we used flow cytometry to assess the effect of BMI1 knockdown on the cell cycle status and apoptosis. We found that Bmi1 depletion induced significant increases in sub-G 1 DNA in both Z138c and REC1 cells (Figure 5b, left panel) . But knocking down Bmi1 did not significantly alter the ratio of cell cycle phases (G 1 : S: G 2 /M) in the examined MCL cells (Figure 5b, right panel) . Consistent with that observation, the cytometric analysis also showed that knocking down BMI1 significantly induced apoptosis in both of these cell lines, although tetracycline (10 mg/ml)-induced cytotoxic effects were also observed at control cells (Figure 5c ).
Cross-linking/chromatin immunoprecipitation (ChIP) assays with Z138c and REC1 cells showed that Bmi1 interacts with BCL2L11 (REC1) and/or PMAIP1 (Z138c and REC1) when specific primer pairs covering the PMAIP1/Noxa or BCL2L11/Bim promoter region were used (see Supplementary Methods). Probes of BCL2L11 promoter were used as described previously. 15 Primers of PMAIP1 were newly designed around promoter region of the gene as shown in Figure 5d . As Z138c has homozygous deletion of BCL2L11, 2-4 we did not perform ChIP assay for Z138c by use of BCL2L11 primers. The binding of Bmi1 was confirmed using ChIP assay with a quantitative PCR system (Figures 5d and e) . Accumulation of Bmi1 was observed around the CpG island of the PMAIP1 (REC1 and Z138c) or BCL2L11 (REC1). Notably, the levels of PMAIP1 (REC1 and Z138c) or BCL2L11 (REC1) were affected by the knocking down BMI1 in these cell lines (Figures 5d and e) , suggesting Bmi1 could 
regulate Noxa (Z138c and REC1) and Bim (REC1), to inhibit apoptosis in these MCL cells. We also performed ChIP assays to determine whether Bmi1 interacts both CDKN2A and PMAIP1 in Jeko1 cells, which have BCL2L11 deletion. As shown in Figure 5d , we found that Bmi1 can interact with both CDKN2A and PMAIP1 in Jeko1 cell line. Our results suggest that Bmi1 negatively regulate not only CDKN2A but also pro-apoptotic genes PMAIP1 and BCL2L11, leading to enhancement of anti-apoptotic potential in MCL.
Bortezomib-induced apoptosis leads to downregulation of Bmi1 and upregulation of miR-16 in MCL Bortezomib is known to be a proteasome inhibitor that has been applied for relapsed MCL cases. 40, 41 We therefore used this drug to assess apoptosis against Z138c and REC1 cells. The IC 50 for bortezomib was 14 nM in Z138c cells and 20 nM in REC1 cells (data not shown). We initially confirmed that bortezomib concentration dependently increased the incidence of apoptosis with increases in the sub-G 1 fraction (Figure 6a ). We then examined the effect of bortezomib on expression of the pro-apoptotic proteins Bim and Noxa, which are likely direct targets of Bmi1. Introduction of bortezomib led to dose-and time-dependent reductions in Bmi1 expression, which reversed the Bmi1-associated inhibition of Noxa (Z138c and REC1) and Bim (REC1; Figure 6b ). By contrast, cells treated with dexamethasone or etoposide showed no reduction of Bmi1 (Figure 6b ). Corresponding to the bortezomib-induced reduction of Bmi1, miR-16 expression was increased in MCL cell lines (Z138c and REC1; Figure 6c) , whereas no such effect was observed with dexamethasone (data not shown) or etoposide treatment. As 10 nM bortezomib effectively reduced Bmi1 expression with upregulation of miR-16 in MCL cell lines, we examined miR-16 expression for a primary sample at recurrence (MCLP1), and found that miR-16 expression was also increased in the primary sample, whereas no such effect was observed with etoposide treatment (Figure 6d ).
DISCUSSION
SP cells are an enriched source of cancer-initiating cells with stemlike properties that have been identified in various cancers. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] We demonstrated that MCL SP cells show clonogenicity as well as a capacity for self-renewal, which is the most important characteristic of cancer stem or initiating cells. 32, 33 Our findings suggest that lymphoma-initiating cells are likely present within the MCL SP, although MCL SP might still remain heterogeneous population. More detailed studies will be required to identify a specific molecular marker that can be used to detect lymphomainitiating cells.
MCL is characterized by t(11;14)(q13;q32), which leads to overexpression of CCND1/cyclin D1 and is presumed to derive from naive pre-germinal center CD5 þ B cells. [1] [2] [3] Despite the presence of this common molecular marker, experiments with transgenic mice overexpressing cyclin D1 proved that this protein cannot, by itself, induce lymphomas; 1,2 additional genomic changes are necessary for lymphomagenesis. To identify those other aberrant changes, several studies using array-based comparative genomic hybridization have been conducted. [4] [5] [6] Those studies showed that genomic imbalances, including gain/ amplification at 3q, 6p, 7p, 8q, 10p, 12q and 18q, and loss/deletion at 1p, 2p, 6q, 8p, 9p, 11q and 13q, frequently occur in MCL. Among these, deletion of 9p21 is seen in about 40-50% of MCL cases and results in dysregulation of the tumor-suppressor gene CDKN2A, which encodes p16 INK4a and p14 ARF . Earlier studies also showed that in several contexts, including lymphoma, BMI1/Bmi1 exerts its oncogenic effects, at least in part, by silencing the CDKN2A tumorsuppressor locus, thereby promoting cell cycle progression and suppressing senescence and apoptosis. 12, 13, 42 In this study, we found that refractory MCL cases exhibit greater expression of BMI1 than do cases at initial diagnosis. This suggests upregulation of BMI1 might be pivotal element associated with the disease progression. Although we were unable to collect sufficient numbers of primary samples to determine what % of refractory cases show BMI1 upregulation, we examined two cases showing upregulation of BMI1/Bmi1 with morphological transformation (MCLP1: classical to pleomorphic; MCLP2: classical to leukemic). We speculate that among refractory cases upregulation of BMI1 may be observed more frequently in those with 9p21 deletion than in those without it, although more samples with and without 9p21 loss will be required to test that hypothesis.
In this study, knocking down BMI1-induced apoptosis but not cell cycle arrest. Despite the absence of CDKN2A, transfection of siBMI1 increased apoptosis in Z138c and REC1 cells. This suggests that in addition to CDKN2A, Bmi1 is able to downregulate proapoptotic genes in MCL, thereby enhancing the anti-apoptotic potential. Recent studies have identified several genes whose targeting by Bmi1 contributes to tumorigenesis. In myeloma cells, for example, Bmi1 negatively regulates the pro-apoptotic gene BCL2L11/Bim to exert an anti-apoptotic action. 15 In addition, Bmi1 promotes Ewing's sarcoma and glioma tumorigenicity independently of CDKN2A repression. 43, 44 Pten, another wellknown tumor suppressor, is also a target of Bmi1, 14 as is PMAIP1Noxa, a pro-apoptotic gene normally expressed for T-cell regulation. 39 Consistent with the last, we also observed that Bmi1 negatively regulates PMAIP1/Noxa in Z138c and REC1 cells, which carry homozygous 9p21 (CDKN2A) deletions. We speculate that Bmi1 exerts an anti-apoptotic effect in vivo, as MCL SP cells showed greater survival capability than MP cells after transplantation into NOG mice. Moreover, the observed difference in survival reflects the greater anti-apoptotic potential of SP cells due, at least in part, to Bmi1-mediated negative regulation of the pro-apoptotic proteins Bim and/or Noxa.
MiRNAs are a class of small non-coding RNAs that have important regulatory roles at the post-transcriptional level by binding to the 3bility than MP cells after transplantation into NOG mice. Moreover, the observedion. Shimono et al. 36 demonstrated that miR-200c negatively regulates BMI1 in breast cancer stem cells and that its dysregulation is strongly associated with tumorigenesis. Several other miRNAs, including miR-15a, miR15b, miR-16, miR-128, miR-194 and miR-200b, are also reportedly able to control BMI1 in various cancers, 11, [34] [35] [36] [37] [38] although their role in cancer stem cells or SP cells remains unknown. MiRNAs associated with MCL tumorigenesis include miR-17-92, miR-29a-c and miR-16. [45] [46] [47] [48] Of those, miR-15a and miR-16 are located at 13q14, a cluster known to be a tumor-suppressor miRNA polycistron. MiR-15a and miR-16 are downregulated in B-cell chronic lymphocytic leukemia. 49 Although recurrent loss of 13q has been observed in MCL, 4 we detected miR-16 expression in the MCL cases we examined, suggesting miR-16 is not targeted for deletion in MCL. Indeed, there have been no reports of a relationship between13q loss and miR-16 downregulation in MCL. In a very interesting report on the role of miR-16 in MCL pathogenesis, Chen et al. 46 showed that CCND1 (cyclin D1) mRNA is truncated, which leads to increased cyclin D1 expression, a larger S-phase cell fraction and alteration of miR-16 binding sites. Those findings led to their conclusion that truncation of CCND1 mRNA in MCL reduces its susceptibility to downregulation by miRNAs, which suggests dysregulation of the cell cycle is a crucial event in the pathogenesis of MCL. However, those investigators did not report the direct target of miR-16 in MCL. In this study, we showed that miR-16 regulates BMI1 expression in MCL SP cells. This finding together with those of Chen et al. strongly suggests that miR-16 is a key regulator whose silencing leads to dysregulation of both the cell cycle and apoptosis in MCL cells.
Other targets of miR-16 identified in various cancers include Bcl2, COX2, Pim-1, SMRT, Wip, cyclin E, Weel and Cdc25. [49] [50] [51] [52] [53] [54] [55] [56] [57] However, the cell cycle-associated genes CCNE1, WEE1 and CDC25 may not be essential targets of miR-16 in MCL, as transfecting MCL cell lines with siBMI1 or miR-16 did not affect their cell cycle profiles. On the other hand, our observation that Bcl2 is upregulated in the MCL SP (Supplementary Figure S2) suggests Bcl2 upregulation could be a direct effect of miR-16 downregulation. Our findings also do not preclude additional targets from contributing to the aggressive tumorigenesis of MCL, although their identification will require further analysis.
The proteasome inhibitor bortezomib, administered alone or in combination with rituximab, has been used to effectively treat refractory MCL and thus improve patient prognoses. 40, 41 In addition, we found that bortezomib induces apoptosis with downregulation of Bmi1 and upregulation of miR-16 in MCL. Our findings are consistent with the clinical results and provide a scientific basis for the use of bortezomib against recurrent MCL. The precise mechanism by which these molecules are targeted should be determined in future studies.
In summary, we have shown for the first time that BMI1/Bmi1 is associated with disease progression in MCL. MCL SP cells exhibit cancer-initiating characteristics that appear to relate to the downregulation of miR-16 and the upregulation of Bmi1, which suppresses expression of the pro-apoptotic genes PMAIP1 and BCL2L11. These findings are the first to provide a rationale for using bortezomib against Bmi1, whose dysregulation may be essential for survival of the MCL-initiating population.
MATERIALS AND METHODS
Primary MCL samples
Tumor specimens obtained from 29 primary MCL samples of 24 patients collected at Akita University Hospital (10 samples), Yamamoto Kumiai Hospital (1 sample), Aichi Cancer Center (14 samples, 9 of the 14 cases was previously described 4 ) and Kurume University (4 samples) were included in the study. Among them, 19 samples were obtained from a lymph node at the time of diagnosis, before administration of any treatment (initial diagnosis). The remaining 10 samples were obtained from a lymph node (9 cases) or peripheral blood (1 case) on recurrence of MCL after a period of CR had been achieved with a first-line chemotherapy such as R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisone) or R-Hyper-CVAD (rituximab, cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine). Of note, the five relapsed samples were obtained from patients who also contributed to the 19 samples obtained at initial diagnosis. Written informed consent was obtained in keeping with institutional policies.
MCL was diagnosed by three expert hematopathologists (Ryo Ichinohasama (Tohoku University, Sendai, Japan), Kouichi Oshima (Kurume University, Kurume, Japan) and Shigeo Nakamura (Nagoya University, Nagoya, Japan)) based on the morphological findings using the definition from the WHO classification of malignant lymphomas. The immunophenotype of the tumors was determined by immunohistochemical analysis of tissue sections and/or flow cytometric analysis of cell suspensions. These studies examined Ig light and heavy chains; several B-cell (CD19, CD20, CD22, CD45RA and CD79a) and T-cell (CD2, CD3, CD5, CD7, CD4, CD8, CD45RO and CD43) markers; CD10; and CD23. CCND1 expression was assessed immunohistochemically in all cases.
SP cells were obtained from two MCL patients at recurrence: MCLP1 and MCLP2. Their detailed information is as follows. MCLP1: 62-year-old female, stage IVA, International Prognosis Index (IPI) low (at initial diagnosis). The surface markers of the tumor were CD20
þ and CD10 À . The chromosomal abnormality was 45XX, add(2)(q21), -7,-9,-10,t(11;14)(q13,q32),-14,-15,-17,-17,-18, þ 8mar. The patient was treated with R-Hyper-CVAD. After three cycles of the treatment, CR was achieved, but 27 months later her MCL recurred, and cells (from lymph node biopsy) were harvested for SP analysis. MCLP2: 63-year-old male, Dysregulation of BMI1 and miR-16 in mantle cell lymphoma K Teshima et al stage IVB, IPI high (at initial diagnosis). The surface markers of the tumor were CD3
þ . Fluorescence in situ hybridization was performed and t(11;14) was confirmed. This patient was treated with six course of R-CHOP, and CR was achieved, after which the patient received autologous peripheral blood stem cell transplantation (auto PBSCT). About 6 months after the auto PBSCT, his MCL recurred, and cells were harvested from his peripheral blood, which contained 92% tumor cells.
Normal CD5 þ B cells or CD19 þ lymphocytes (B cell) were collected from a healthy volunteer donor in Akita University Hospital for a tonsillectomy. The collected cells were stained for CD5 (phycoerythrin) and CD19 (fluorescein isothiocyanate) and sorted using MoFlo (Dako, Glostrup, Denmark).
Cell lines
A panel of seven MCL-derived cell lines (Z138c, REC1, Jeko1, SP53, JVM2, NCEB1 and G519) were used. 4 All these lines have been thoroughly characterized in terms of their morphology, immunophenotype and/or interphase cytogenetics (detection of t(11;14)(q13;q32)). FL18, a follicular lymphoma cell line, 4, 45, 48 was kindly provided from Dr T Yoshino of Okayama University, Japan. 4, 45, 48 Three other B-cell lymphoma cell lines (OCI-Ly3, SUDHL4 and Raji) were also used for SP detection and miRNA screening. The culture medium was RPMI supplemented with 10% fetal calf serum. Rat-1 cells derived from rat fibroblasts were obtained from the RIKEN Bioresource Center (Tokyo, Japan) and cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. 48 
SP analysis
To identify the SP among MCL cells, the cells were resuspended at a concentration 1 Â 10 6 cells/ml in Hank's balanced salt solution supplemented with 2% fetal calf serum, 10 mmol/l HEPES and 5 mg/ml Hoechst 33342 dye, and incubated for 60 min at 37 1C with intermittent shaking. As a negative control, SP cells were preincubated with 100 mmol/l verapamil or 50 mmol/l reserpine, two ABC transporter inhibitors. See Supplementary Methods for details.
CFC assay
Cellular potential for clonogenicity of SP and MP cells was determined using CFC assay. Briefly, 5 Â 10 3 sorted SP and non-SP cells were plated in duplicate cultures containing 1 ml RPMI 1640 with 1% methylcellulose, 30% fetal calf serum, 10-4 M 2-mercaptoethanol (Methocult; Stem Cell Technologies, Vancouver, BC, Canada), plus a cocktail of growth factors (50 ng/ml rh stem cell factor, 10 ng/ml rh granulocyte-macrophage colonystimulating factor, 10 ng/ml rh interleukin-3, and 3 U/ml erythropoietin).
In vivo transplantation to NOG mouse ) were subcutaneously injected into the right or left side of the body of 6-to 8-week-old female NOD/Shi-scid IL-2gnul (NOG) mice (Central Institute for Experimental Animals, Kawasaki, Japan). 58 Caliper measurements of tumor diameters were done every 3 days. In vivo experiments were done in accordance with the institutional guidelines for the use of laboratory animals.
Real-time quantitative PCR analysis
Real-time quantitative PCR was performed by use of TaqMan method (Applied Biosystems, Foster City, CA, USA). Taqman probes were purchased from Applied Biosystems. miRNA levels and mRNA were separately normalized with U47 or glyceraldehyde 3-phosphate dehydrogenase, and the relative expression level of specific miRNA and mRNA was presented by 2 -DDCt . See Supplementary Methods for details.
Western blot analysis
Antibodies were all purchased from Cell Signaling Technology (Danvers, MA, USA). See Supplementary Methods for details.
Cell cycle and apoptosis analyses
For cell cycle analysis, the cellular DNA content was then measured using a FACS calibur flow cytometer running the CELL Quest program (BD Biosciences, San Jose, CA, USA). An annexin V-phycoerythrin apoptosis detection kit (BD Biosciences) was used to assess the incidence of apoptosis. See Supplementary Methods for details.
Transfection of siRNA or pre-microRNA 
Luciferase reporter assay
The pMIR control vector (Life Technologies, Tokyo, Japan) encoding firefly luciferase was modified such that the BMI1 3 0 UTR was inserted into the SpeI site and HindIII site immediately downstream from the stop codon. See Supplementary Methods for details.
Chemicals
Bortezomib (Vercade) was purchased from LC laboratories (New Boston Street, Woburn, Canada). Etoposide, dexamethasone, tetracycline and puromycin were from Sigma (St Louis, MO, USA).
Statistical analysis
Fisher's exact test was used for comparison between two groups of frequencies of gain or loss for each single clone, and the Mann-Whitney U-test for detecting significant differences in expression levels of BMI1 between MCL cases at ID and R. Other P-values (for example, BMI1 expression SP and MP, CFC assay between SP and MP) were calculated using Student's t-test.
